Novartis division Sandoz inaugurates facility in Maharashtra for oral cancer medicines

The plant, which is spread over 32,000 square metres, would cater to the export markets, it added.

Published On 2022-07-01 08:00 GMT   |   Update On 2022-07-01 08:00 GMT

New Delhi: Drug firm, Novartis India, has recently announced that the company's division Sandoz Technical Operations has inaugurated a new manufacturing facility in Maharashtra.

The plant at Kalwe would produce oral cancer medicines for the global markets and will play a key role towards enabling the delivery of high-quality cancer treatment, the drug maker said in a statement. 
The plant, which is spread over 32,000 square metres, would cater to the export markets, it added. 
The new facility currently has a workforce of 70 people and the company plans to recruit more employees to support the expansion of the production capacity.

Sanjay Murdeshwar, Country President, Novartis India said, "This marks an important milestone for us at Novartis, and particularly for our Sandoz division, a global leader in generic pharmaceuticals and biosimilars. The inauguration of the new production and launch site for Oncology oral solids at Kalwe in India is a step forward in our constant endeavour to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Moreover, the launch of this facility will support the government's 'Make in India' vision to find solutions for the evolving needs of patients around the world."

Founded in 1947, Novartis India Ltd. is a pharmaceutical company headquartered in India. The Pharmaceutical business of the company is focused on Bone & Pain, Calcium portfolio, Gynecology and Neurosciences and the Generics business is focused on Gynecology, Anti-TB and Anti-infectives.

Novartis has three legal entities -- Novartis Healthcare Pvt Ltd, Novartis India and Sandoz Pvt Ltd, employing more than 10,000 people.

Read also: Novartis division Sandoz application for proposed biosimilar Hyrimoz's high concentration formulation accepted by EMA

Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News